Simultaneous treatment with 1-β-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells
- Author
- TAKEMURA, Haruyuki1 ; URASAKI, Yoshimasa1 ; YOSHIDA, Akira1 ; FUKUSHIMA, Toshihiro1 ; UEDA, Takanori1
[1] First Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan - Source
Cancer research (Baltimore). 2001, Vol 61, Num 1, pp 172-177 ; ref : 42 ref
- CODEN
- CNREA8
- ISSN
- 0008-5472
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anthracyclines Anticancéreux Association médicamenteuse Chronique Cytarabine Cytidine deaminase DNA topoisomerase (ATP-hydrolysing) Daunorubicine Deoxycytidine kinase Glutathion Glycoprotéine P Homme In vitro Leucémie myéloïde Lignée HL60 Lignée cellulaire établie Mécanisme action Pyrimidine nucléoside Résistance croisée Résistance multiple Protéine MRP Enzyme Hydrolases Hémopathie maligne Isomerases Myéloprolifératif syndrome Transferases
- Keyword (en)
- Anthracyclins Antineoplastic agent Drug combination Chronic Cytarabine Cytidine deaminase DNA topoisomerase (ATP-hydrolysing) Daunorubicin Deoxycytidine kinase Glutathione P Glycoprotein Human In vitro Chronic myelocytic leukemia HL60 cell line Established cell line Mechanism of action Pyrimidine nucleoside Cross resistance Multiple resistance Enzyme Hydrolases Malignant hemopathy Isomerases Myeloproliferative syndrome Transferases
- Keyword (es)
- Antraciclinas Anticanceroso Asociación medicamentosa Crónico Citarabina Cytidine deaminase DNA topoisomerase (ATP-hydrolysing) Daunorubicina Deoxycytidine kinase Glutatión Glicoproteína P Hombre In vitro Leucemia mieloidea Línea HL60 Línea celular establecida Mecanismo acción Pirimidina nucleósido Resistencia cruzada Resistencia múltiple Enzima Hydrolases Hemopatía maligna Isomerases Mieloproliferativo síndrome Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 877224
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"61\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"172\";s:8:\"\u0000*\u0000epage\";s:3:\"177\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TAKEMURA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Haruyuki\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:18:\"URASAKI, Yoshimasa\";i:1;s:14:\"YOSHIDA, Akira\";i:2;s:20:\"FUKUSHIMA, Toshihiro\";i:3;s:14:\"UEDA, Takanori\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"61\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"172\";s:8:\"\u0000*\u0000epage\";s:3:\"177\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TAKEMURA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Haruyuki\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:18:\"URASAKI, Yoshimasa\";i:1;s:14:\"YOSHIDA, Akira\";i:2;s:20:\"FUKUSHIMA, Toshihiro\";i:3;s:14:\"UEDA, Takanori\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"61\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"172\";s:8:\"\u0000*\u0000epage\";s:3:\"177\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TAKEMURA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Haruyuki\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:18:\"URASAKI, Yoshimasa\";i:1;s:14:\"YOSHIDA, Akira\";i:2;s:20:\"FUKUSHIMA, Toshihiro\";i:3;s:14:\"UEDA, Takanori\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"61\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"172\";s:8:\"\u0000*\u0000epage\";s:3:\"177\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TAKEMURA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Haruyuki\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:18:\"URASAKI, Yoshimasa\";i:1;s:14:\"YOSHIDA, Akira\";i:2;s:20:\"FUKUSHIMA, Toshihiro\";i:3;s:14:\"UEDA, Takanori\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"61\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"172\";s:8:\"\u0000*\u0000epage\";s:3:\"177\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TAKEMURA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Haruyuki\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:18:\"URASAKI, Yoshimasa\";i:1;s:14:\"YOSHIDA, Akira\";i:2;s:20:\"FUKUSHIMA, Toshihiro\";i:3;s:14:\"UEDA, Takanori\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:169:\"Simultaneous treatment with 1-\u03b2-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
